When considering all large thyroid nodules > 4 cm, false negative rates declined compared with considering only large nodules in patients that had undergone surgery, in a new analysis.
Thyroid cancer rates among transgender female veterans appear similar to those in cisgender women. Experts urge a cautious interpretation of the recent study results.
No significant differences in nondiagnostic results or hematomas seen when the blood thinners are continued, while discontinuing the medications may have risks.
With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.